Prophylactic use of granulocyte colony-stimulating factor after chemotherapy does not affect survival rate in acute myeloid leukemia: a meta-analysis

Acta Haematol. 2009;121(4):223-6. doi: 10.1159/000225909. Epub 2009 Jun 19.

Authors

Jing Wang¹, Li An, Shi Chen, Jian Ouyang, Rongfu Zhou, Bing Chen, Yonggong Yang

Affiliation

¹ Department of Hematology, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, PR China.

PMID: 19546524
DOI: 10.1159/000225909

No abstract available

Publication types

Meta-Analysis

MeSH terms

Acute Disease
Adolescent
Aged
Aged, 80 and over
Antineoplastic Agents / adverse effects*
Filgrastim
Granulocyte Colony-Stimulating Factor / therapeutic use*
Humans
Lenograstim
Leukemia, Myeloid / drug therapy
Leukemia, Myeloid / mortality*
Middle Aged
Neutropenia / chemically induced
Neutropenia / prevention & control*
Randomized Controlled Trials as Topic / statistics & numerical data
Recombinant Proteins / therapeutic use

Substances

Antineoplastic Agents
Recombinant Proteins
Granulocyte Colony-Stimulating Factor
Lenograstim
Filgrastim